Tigenix NV (G9U.BR)
BRIEF-Takeda Says Announces Voluntary And Conditional Public Takeover Bid For Outstanding Shares,Warrants And American Depositary Shares Of Tigenix NV To Commence April 30, 2018
* SAYS ANNOUNCES VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID FOR OUTSTANDING SHARES, WARRANTS AND AMERICAN DEPOSITARY SHARES OF TIGENIX NV TO COMMENCE APRIL 30, 2018 Source text for Eikon: Further company coverage: (Reporting By Chris Gallagher)
* FY OPERATING LOSS OF EUR 53.2 MILLION VERSUS LOSS OF EUR 3.0 MILLION YEAR AGO
BRIEF-Tigenix And Takeda Announce Alofisel® (Darvadstrocel) Receives Approval To Treat Complex Perianal Fistulas In Crohn's Disease In Europe
* TIGENIX AND TAKEDA ANNOUNCE ALOFISEL® (DARVADSTROCEL) RECEIVES APPROVAL TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE IN EUROPE
PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video
* TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007
LONDON An $11 billion (8.12 billion pounds) burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.
LONDON An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.
TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).